The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
Mange lægemidler er udpeget som det nye mirakelmedicin mod COVID-19, men har skuffet. Her er nogle af dem. Det er
- Andreas Andersen
- 6. december 2021
- 0
Mange lægemidler er udpeget som det nye mirakelmedicin mod COVID-19, men har skuffet. Her er nogle af dem. Det er derfor der skal dokumentation for […]
Hvad fik vi egentlig for de knap 4 millioner skattekroner Mehlsen fik? Han havde en økonomisk interesse i at påvise
- Andreas Andersen
- 10. marts 2023
- 0
Hvad fik vi egentlig for de knap 4 millioner skattekroner Mehlsen fik? Han havde en økonomisk interesse i at påvise bivirkninger, fordi i dag har […]
@CBrunsholm @Medicinmanden På vores sygehus er status lige nu at 75% af de COVID-19 positive er isoleret, resten er afisoleret.
- Andreas Andersen
- 10. februar 2022
- 0
@CBrunsholm @Medicinmanden På vores sygehus er status lige nu at 75% af de COVID-19 positive er isoleret, resten er afisoleret. Man er ikke indlagt lige […]
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.